Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?

The million-dollar question remains the optimal sequencing and combination of ICIs to optimize oncologic outcomes for these patients. The big challenge lies in defining the thin line between utilizing the right window of opportunity to cure disease and jeopardizing proven therapies for metastatic disease

Automated summary

The optimal sequencing and combination of ICIs to enhance oncologic outcomes for these patients remains a million-dollar question, as it is challenging to strike a delicate balance between utilizing the right window of opportunity to cure the disease and jeopardizing proven therapies for metastatic disease.